Tempus reported a 36% year-over-year jump in Q1 revenue to $348.1 million and raised full-year guidance, reinforcing investor focus on its AI-driven diagnostics and data platform. The Chicago-based company said diagnostics revenue climbed 35% to $261.1 million, with oncology volume growth contributing and minimal residual disease (MRD) testing volume rising to about 6,500 tests after a roughly sixfold increase. Management also highlighted platform momentum, including multimodal data and AI model deployment. Tempus noted a multi-year collaboration with Merck to accelerate biomarker discovery and development using its Lens analytical platform, and an expanded collaboration with Gilead to provide enterprise-wide access to Lens and related datasets for oncology pipeline work. While revenue and guidance improved, Tempus also reported higher costs, including increased R&D and SG&A, and a wider net loss for the quarter. The company ended Q1 with $521.2 million in cash and cash equivalents. For the broader sector, the update strengthens the argument that real-world clinical testing volume and algorithmic iteration are converging into a measurable growth engine for precision oncology vendors.